Word

CRISPR THERAPEUTICS DE&I IT'S IN OUR DNA DIVERSITY, EQUITY, AND INCLUSION

Status

Pending

Status Code

730

Status Date

Thursday, May 9, 2024

Serial Number

97635376

Mark Type

4

Filing Date

Monday, October 17, 2022

Published for Opposition

Tuesday, October 3, 2023

Trademark Owner History

CRISPR Therapeutics AG - Owner At Publication

Classifications

41 Education services, namely, providing on-line non-downloadable articles and newsletters in the field of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy

42 Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals

CRISPR THERAPEUTICS DE AND I IT IS IN OUR DNA DIVERSITY EQUITY AND INCLUSION
as to "CRISPR THERAPEUTICS" has become distinctive of the goods/services through the applicant's substantially exclusive and continuous use of the mark in commerce that the U.S. Congress may lawfully regulate for at least the five years immediately before the date of this statement; CRISPR THERAPEUTICS has become distinctive of the goods/services as evidenced by the ownership on the Principal Register for the same mark for sufficiently similar goods/services of active U.S. Registration No(s). 6724517

Trademark Events

Oct 20, 2022

Teas Change Of Correspondence Received

Oct 20, 2022

New Application Entered

Oct 20, 2022

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Oct 20, 2022

Attorney/Dom.Rep.Revoked And/Or Appointed

Nov 1, 2022

New Application Office Supplied Data Entered

Mar 31, 2023

Assigned To Examiner

Mar 31, 2023

Non-Final Action Written

Mar 31, 2023

Non-Final Action E-Mailed

Mar 31, 2023

Notification Of Non-Final Action E-Mailed

Jun 30, 2023

Application Extension To Response Period - Received

Jun 30, 2023

Application Extension Granted/Receipt Provided

Jul 18, 2023

Teas Response To Office Action Received

Jul 18, 2023

Correspondence Received In Law Office

Jul 18, 2023

Teas/Email Correspondence Entered

Aug 30, 2023

Approved For Pub - Principal Register

Sep 13, 2023

Notification Of Notice Of Publication E-Mailed

Oct 3, 2023

Published For Opposition

Oct 3, 2023

Official Gazette Publication Confirmation E-Mailed

May 9, 2024

Sou Extension 1 Filed

May 9, 2024

Sou Extension 1 Granted

May 9, 2024

Sou Teas Extension Received

Nov 28, 2023

Noa E-Mailed - Sou Required From Applicant

May 10, 2024

Notice Of Approval Of Extension Request E-Mailed